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Background: The immune system has a central role in controlling cancer, and factors that influence protective antitumour
immunity could therefore have a significant impact on the course of malignant disease. Opioids are essential for the management
of cancer pain, and preclinical studies indicate that opioids have the potential to influence these tumour immune surveillance
mechanisms. The aim of this systematic literature review is to evaluate the clinical effects of opioids on the immune system of
patients with cancer.
Methods: A systematic search of Ovid MEDLINE (PubMed) and Embase, Cochrane database and Web of Knowledge for clinical
studies, which evaluated the effects of opioids on the immune system in patients with cancer, was performed.
Results: Five human studies, which have assessed the effects of opioids on the immune system in patients with cancer, were
identified. Although all of these evaluated the effect of morphine on immunologic end points in patients with cancer, none
measured the clinical effects.
Conclusions: Evidence from preclinical, healthy volunteer and surgical models suggests that different opioids variably influence
protective anti-tumour immunity; however, actual data derived from cancer populations are inconclusive and definitive
recommendations cannot be made. Appropriately designed and powered studies assessing clinical outcomes of opioid use in
people with cancer are therefore required to inform oncologists and others involved in cancer care about the rational use of
opioids in this patient group.
The innate and adaptive immune systems provide crucial
protection against pathogenic organisms and cancer (Gaspani
et al, 2002; Shavit et al, 2004; Nu¨ssler et al, 2007). Cancer
immunosurveillance involves natural killer (NK) cells that have an
inherent (innate) capacity to recognise and kill tumours via cell
surface molecules (Table 1), the secretion of immunoregulatory
cytokines and the actions of white blood cell (lymphocyte) subsets,
which control and regulate anti-tumour immunity (T ‘helper’ or
CD4þ T cells) or recognise and kill transformed cells (‘cytotoxic’ T
or CD8þ T cells) (Table 1) (Foulds et al, 2013).
The importance of immunosurveillance in the context of
cancer has been illustrated by a number of findings. High NK
cell cytotoxicity and high concentrations of cytotoxic T cells are
associated with a reduced progression of disease and better
survival in patients with colorectal cancer (Nu¨ssler et al, 2007;
Pages et al, 2009). In contrast, rodent studies using the MADB106
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(mammary adenocarcinoma) cell line have shown that tumour
burden can increase if NK cell cytotoxicity is reduced (Gaspani
et al, 2002; Shavit et al, 2004). Furthermore, the incidence of
secondary cancers is higher in patients who have had chemo-
therapy for a primary cancer (Morton et al, 2013). The effect of
immune system impairment can also be selective, as there is a higher
incidence of non-Hodgkin’s lymphoma, lip cancer and melanoma in
transplant recipients on immunosuppressive treatment, whereas the
incidence of leukaemia, lung, kidney and urinary tract cancers
remained the same (Van Leeuwen et al, 2010).
The central role that the immune system has in protecting
against cancer means that any factors that influence protective
anti-tumour immunity are likely to have a profound impact on the
course of disease. Although opioids are essential for the manage-
ment of cancer pain, numerous in vitro, animal and volunteer
models have reported opioids to have a number of immuno-
regulatory effects. These are dependent on the opioid being tested,
the component of the immune system that is being influenced, the
administration schedule and also the experimental model (Van Der
Laan et al, 1996; West et al, 1997; Martucci et al, 2004). Given the
evidence that opioids have the capacity to influence anti-tumour
immunity, it is important to better understand the potential clinical
impact of opioid usage in this context.
Although the immune effects of opioids in patients with
cancer have been reviewed previously (Budd, 2006; Pergolizzi et al,
2008; Sacerdote, 2008), there has been no systematic review
of the literature assessing the effects of opioids on anti-tumour
immune potential in patients with cancer and how these
effects could influence the clinical management. The immunologic
consequences of opioids that are administered to patients
with chronic cancer pain over a period of several months are
likely to be very different to those that are induced by the relatively
short treatments that are administered to healthy volunteers or
patients post-surgery, because of the differing immunologic
phenotypes of these groups (Snyder and Greenberg, 2010; Colvin
et al, 2012; Heaney and Buggy, 2012; Foulds et al, 2013;
Galizia et al, 2013). We therefore conducted a new systematic
review of the literature relating to the effects of a broad
range of therapeutic opioids on immunologic parameters that are
relevant to protective anti-cancer immunity in non-surgical
clinical studies.
It is becoming apparent that an individualised approach to
cancer pain treatment is essential, as the analgesic properties and
side effects of opioids exhibit great interindividual variability
(Ahmedzai, 2013), as do their influence on immune cell function
(Thomas et al, 1995; Jacobs et al, 1999). Furthermore, even if
opioids were to have immunomodulatory effects in patients, this
would only be of clinical interest and relevant to prescribers if these
significantly influenced tumour growth, metastasis, infection and/
or other clinical outcomes.
We have identified five studies that evaluated the effect of
opioids on immune function in patients with cancer. However, the
literature indicates that only the effect of morphine has been
evaluated, and none of the studies have reported on relevant
clinical end points.
MATERIALS AND METHODS
Search strategy and selection criteria. The aim of this review was
to identify all relevant non-surgical clinical studies that have
evaluated the effects of opioids on the immune system in patients
with cancer. On 8 November 2013, the electronic databases Ovid
MEDLINE (PubMed) and Embase (Ovid MEDLINE(R) 1946 to
Present and Ovid MEDLINE In-Process and Other Non-Indexed
Citations, and Embase 1974 to 2013 Week 29), Cochrane database
and Web of Knowledge were searched using the terms and dates
listed below. These were devised to be inclusive of all potentially
relevant studies and have been extended to include terms relating
to other conditions that are mapped to Medical Subject Heading
(MeSH) terms as well as searching for these terms as text word
searches to increase the search sensitivity. To search for opioids,
the search terms used were: opioid OR opiate OR morphine OR
codeine OR buprenorphine OR methadone OR tramadol OR
tapentadol OR oxycodone OR heroin OR fentanyl OR hydro-
morphone OR oxymorphone. These were combined with a search
for cancer OR neoplasm and immunity: including immune* OR
NK cell OR T cell. The limits were English language; clinical trial
(any); adults; humans; all adult (MEDLINE) from 1974 to 2013. All
titles and abstracts were reviewed to assess their relevance for
inclusion. The results of these searches are shown in the PRISMA
Flow Diagram (Figure 1; Moher et al, 2009).
Table 1. Role and activation pattern of the main immune cells
Cell Role Activators Mechanism of activity Arm
Dendritic cell Antigen presentation Multiple, including bacterial
products and cytokines
Presentation of antigenic peptides in the context of MHC
class I and II molecules and the delivery of essential
costimulatory molecules
Innate
Natural killer cell Anti-tumour
Anti-viral
Multiple, including the lack of
MHC class I expression
Release of cytotoxic molecules (granzymes, perforin) Innate
Neutrophil Anti-bacterial/-fungal Opsonisation Phagocytosis and oxidative burst Innate
Monocyte–macrophage
lineage
Anti-bacterial/-fungal Opsonisation
Antigen presentation
Phagocytosis and oxidative burst Innate
CD4þ T cell Immune coordination/
regulation
Antigenic peptides presented by
MHC class II plus essential
costimulatory molecules
Regulating the activity of other immune cells Adaptive
CD8þ T cell Cytotoxicity Antigenic peptides presented by
MHC class I
Induction of apoptosis by (i) release of cytotoxins
(perforin, granulysin, granzymes), (ii) direct cell–cell
contact, by upregulating surface Fas ligand
Adaptive
B cell Antibody production Antigens binding to surface
immunoglobulin with help from
CD4þ T cells
Antibody production Adaptive
Abbreviations: CD¼ cluster of differentiation; MHC¼major histocompatibility complex.
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In addition to the electronic search, reference lists from
identified reviews and key publications were manually searched.
Articles were also identified through searches of the authors’ own
files, previous reviews on opioid-induced immunosuppression and
outputs from prominent researchers in the field. Only papers
published as full-text articles in English were reviewed. Surgical
studies, patients undergoing cancer surgery, healthy volunteer
studies and animal studies were excluded from this systematic
review, as these groups have different opioid usage, immune
system activation and receptor expression compared with patients
on long-term opioids for cancer pain (Snyder and Greenberg, 2010;
Colvin et al, 2012; Heaney and Buggy, 2012; Foulds et al, 2013;
Galizia et al, 2013). Patients undergoing surgery are also exposed to
a range of drugs during the operation, which potentially impact on
immune function (Colvin et al, 2012; Heaney and Buggy, 2012).
Furthermore, the effect of opioids in patients undergoing cancer
surgery has been reviewed elsewhere (Colvin et al, 2012; Heaney
and Buggy, 2012). As the data are only relevant if opioids have
significant clinical effects, we specifically looked for articles that
assessed clinical effects.
Two authors (JB and KM) undertook independent electronic
literature searches and reviewed all titles and abstracts. Full papers
were retrieved for those fulfilling the criteria, and also for those
publications for which the ability to assess their eligibility could not
be assessed on the basis of the titles and abstracts alone. Two
review authors (JB and KM) then assessed the full text of all
potentially relevant studies. Disagreement at all stages was resolved
by consensus and with recourse to a third review author (AGP).
Data extraction, assessment and analysis. JB and KM indepen-
dently extracted data regarding study design and results and
assessed their quality. Data extracted were the type of study, study
setting, study population (cancer type, stage, treatment) opioid
used, dose and clinical outcome measures (e.g. survival). The
methodologic quality of each study was independently assessed by
JB and KM using Quality Assessment of Studies of Diagnostic
Accuracy included in Systematic Reviews (QUADAS-2) (Whiting
et al, 2011).
RESULTS
This systematic review of the effects of therapeutic opioids on
immune function in patients with cancer identified five studies that
were eligible for inclusion (Table 2). All were found to be
prospective observational studies and no randomised controlled
trials have been undertaken. These clinical studies have focused on
the effects of opioids on markers of immune function, rather than
on relevant clinical outcomes. All studies examined the effects of
morphine – no other opioids have been investigated.
The quality of studies was determined using a QUADAS-2
analysis (Whiting et al, 2011). Included studies had a low risk of
bias (patient selection, index test and flow and timing) and an
unclear risk of reference standard. The two studies by Provinciali
et al (1991, 1996) had an unclear patient selection risk. All studies
had a low risk for applicability concerns (patient selection, index
test and reference standard).
Makimura et al (2011) attempted to find markers that could
predict resistance to morphine treatment by examining the plasma
concentrations of 26 cytokines before and after morphine
treatment in 44 patients with metastatic cancer (Table 2). They
observed interindividual variability in baseline plasma cytokine
concentrations and found no significant changes in the levels of
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Figure 1. PRISMA flow diagram.
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Table 2. Summary of the effect of opioids on immune function in patients with cancer
Author
(year) Research question
Patient
population
Study design and method
of recruitment
Interventions (opioid and
doses) and comparator
Assoc. between opioid
and immune function
Makimura
et al (2011)
Are plasma cytokine
levels potential
biomarkers for
predicting resistance to
morphine treatment in
opioid-naive cancer
patients?
44 Patients
Age 69 (40–85)
years
50% Men
93% Metastatic
cancer
PS status 1 (20%),
2 (55%), 3 (23%),
4 (2%)
Prospective observational study
Cytokines measured at baseline
and compared with samples after
8 days of opioid treatment
Morphine titrated as per a
standardised protocol (dose not
specified)
Morphine – doses not specified
Patients acted as own controls,
baseline samples compared with
day 8
None (except MIP-1a level
decreased (P¼ 0.03) but multiple
comparisons) (baseline:
7.2±19.3 pgml 1 vs day 8
2.3±7.4 pg/ml1)
Plasma IL-12 (p40) level
decreased nonsignificantly
(P¼ 0.07) (baseline:
7.0±17.4 pgml 1, day 8:
2.7±7.6 pgml 1)
No clinical end points measured
Hashiguchi
et al (2005)
Do morphine and its
metabolites modulate
immune function in
advanced cancer
patients?
14 Patients
Age 28–76 years
53% Men
Mixed-stage IV
cancers
(including breast,
tongue,
sarcomas)
PS – not
documented
Group 1: 6
patients, opioid
naive
Group 2: 8
patients on
morphine for 1
month
Prospective observational study
Bloods at enrollment (phase 1), 1
week after starting or changing
morphine dose/route (phase 2)
and 2 weeks after phase 2 (phase
3). Phase 2 was between 10 and
21 days after phase 1
Limitations – 1 patient in group 2
excluded from phase 2 analysis; 2
in group 1, and 4 in group 2
excluded from phase 3 analysis
due to deterioration
Group 1, final morphine dose
20–30mg (routes: oral,
intravenous) group 2: starting
morphine dose 40–120mg (oral, 1
rectal); final morphine dose 20–
240mg (routes: oral, intravenous,
subcutaneous, rectal)
Patients acted as own controls
Negative correlation in Group 1
between morphine, M3G and
M6G and immunoglobulin’s and
PHA-induced lymphocyte
proliferation but not NK cell
activity or CD4/CD8 ratio
Poor correlation for all
immunologic markers in Group 2
No clinical end points measured
Provinciali
et al (1991)
How does morphine
affect NK and LAK cell
activity in neoplastic
patients?
20 Patients with
cancers of
different origins
(including breast,
lung, ovarian and
prostate)
Age, gender,
cancer stage, and
PS status not
reported
Prospective observational study
Blood analysed 1 month after
starting treatment and compared
with healthy volunteers
(transfusion centre)
Limitations – no baseline analysis
N¼9 p.o. morphine±30mg per
day
N¼6 i.t. morphine patients
4±1.5mg per day
N¼5 opioid-naive patients
Three patients acted as own
controls from p.o. morphine to
subsequent i.t. treatment
Blood from healthy subjects
provided by transfusion centre
Sig reduced NK cell activity
(Po0.05)
NK cell activity reduced further
with i.t. than p.o.
LAK cell activity significantly
increased
LAK cell activity higher in p.o.
than i.t. (Po0.005)
No clinical measurements
Provinciali
et al (1996)
How does short- or long-
term morphine
administration affect NK/
LAK activities?
18 Patients
(breast, lung,
ovary, prostate,
bladder, colon,
larynx, stomach
and kidney
cancer)
Age, gender,
cancer stage and
PS status not
reported
10 patients
treated with
morphine
8 patients had no
opioids
Prospective interventional study
Short term – 9 patients treated
with i.v. 10mg morphine (4
pretreated with 5mg p.o.
bromocriptine). Blood checked at
baseline and after 30min
Long-term p.o. morphine
(90±30mg) for 1 month
Limitations – 8 controls low/no
pain, 10 active patients had high
levels of pain
Morphine:10mg i.v. in short-term
study 90±30mg per day p.o. for
1 month in long term study
N¼8 opioid naive cancer patients
as controls
Short term: Cytotoxicity of NK
cells reduced 113±62 vs
44±44 LU20/10
7 (P¼ 0.01)
Increased LAK activity 169±45
vs 252±62 LU20/10
7 (P¼ 0.02)
No change in the number of
peripheral lymphocytes or %
CD3, CD4, CD8, CD16, CD56þ
cells
Long term: NK cell activity
reduced in morphine group vs
those not treated 89±23 vs
171±27 LU20/10
7 (Po0.001)
Higher LAK activity in morphine-
treated
Daudi: 1581.5±1325.0 vs
408.0±24.15 (P¼0.04)
K562: 4420.4±3351.2 vs
1229.0±1643 (P¼0.02)
Higher % of CD3þ and CD4þ
increased in morphine-treated
CD3 (%): 50±4 vs 44±8
(Po0.05)
CD4 (%): 31±3 vs 25±5
(Po0.05)
% CD8þ not affected by
morphine treatment 12±1 vs
13±3
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any cytokine (including interleukin-2 (IL-2)) after 8 days of
treatment with morphine in previously opioid naive patients. This
contrasts with the study by Palm et al (1998), which showed that
the synthesis and secretion of IL-2 by lymphocytes increased
significantly after 4 weeks of morphine treatment in 10 patients
with chronic pain (including three with cancer). No clinical end
points, for example, cancer progression- or disease-free survival
were evaluated in either study (Palm et al, 1998, Makimura et al,
2011). This may suggest that the acute effects of opioids (over days)
on the immune system differ from those that are induced following
chronic exposure (over weeks).
The possibility that the immunologic consequences of opioids
(morphine) depends on the nature of the exposure has been
confirmed in a study of 15 patients with advanced cancer by
Hashiguchi et al (2005) (Table 2), which reported that the impact
of opioids on immune function might correlate with the duration
of opioid administration. They found a negative correlation
between the levels of morphine metabolites and circulating
immunoglobulin levels and the in vitro proliferation of peripheral
blood lymphocytes in response to phytohaemagglutin (a non-
specific activator of T cells) in patients who had just commenced
on morphine. In contrast, no such effects were observed in patients
who had been on morphine for over 1 month. Once again, no
clinical parameters were measured.
Patients with a variety of cancers (including breast, lung,
ovarian and prostate) on oral or intrathecal morphine have been
reported to exhibit a lower NK cell activity and increased
lymphokine-activated killer (LAK) cell activity than untreated or
healthy controls (Table 2; Provinciali et al, 1991). The observation
that intrathecally delivered morphine had a more profound effect
than oral morphine suggests an important role for a centrally
mediated effect. However, only a very small number of patients was
studied and no clinical correlates were investigated (Provinciali
et al, 1991). In a subsequent study, Provinciali et al (1996)
determined the short-term immune effects (at 30min) after a
single 10mg intravenous dose of morphine and the long-term
effects after 1 month of oral morphine (90±30mg per day) on NK
and LAK cell cytotoxicity in 18 patients with cancer (including
breast, lung, ovary and prostate). These cytotoxicity responses were
compared with baseline measurements, and those that were
present before opioid treatment in the short-term experiments
and in cancer patients not on opioids in the long-term study. This
study demonstrated that both acute and chronic morphine
administration reduced NK cell activity and increased LAK
activity. Chronic morphine administration has also been shown
to increase the proportion of CD3þ and CD4þ T cells in
peripheral blood mononuclear cell preparations, whereas the
prevalence of CD8þ T cells is unaffected and the proportion of
CD16þ lymphocytes is reduced. CD16 is a member of the Fc
receptor family that is instrumental for the induction of antibody-
dependent cellular cytotoxicity (ADCC). Antibody-dependent
cellular cytotoxicity is a mechanism of cell-mediated immune
defence and a decrease in the presence of such cells might therefore
negatively impact on tumour surveillance. None of these
parameters were affected during acute morphine administration
(Provinciali et al, 1996). The number of patients in this study was
also small, their cancers were different and once again no clinical
measurements of tumour progression or survival were measured.
In summary, the studies included here suggest that the influence
of morphine on immune potential could be dependent on whether
it is administered acutely or chronically, the route of administra-
tion and also the immune parameters that are considered. These
observations cannot be extrapolated to all opioids due to the
heterogeneous physicochemical and pharmacologic properties of
this broad class of drugs (Sacerdote et al, 1997; Keiser et al, 2009).
Furthermore, the most important outcome – the clinical impact of
these immune influences on cancer progression and patient
survival – remains unexplored.
DISCUSSION
The management of pain is essential, as its immunosuppressive
properties can influence cancer growth in animal models (Page
et al, 2001; Gaspani et al, 2002; Page, 2003, 2005). Fears of
precipitating serious toxicity and the risk of dependence and
Table 2. ( Continued )
Author
(year) Research question
Patient
population
Study design and method
of recruitment
Interventions (opioid and
doses) and comparator
Assoc. between opioid
and immune function
Decrease % CD16þ cells in
morphine treatment 13±3 vs
20±6 (Po0.05)
No clinical end points
Palm et al
(1998)
Does prolonged oral
treatment with sustained
release morphine tablet
influence immune
function?
10 Patients (3
advanced cancer
related pain; 7
non-malignant
pain)
Age 51.5 (37–65)
years
60% Men
PS not reported
Eight age- and
sex-matched
healthy controls
Prospective observational study
Blood samples before initiation of
morphine treatment and after 1, 4
and 12 weeks
Morphine dose 30–240mg per
day
Patients acted as own controls
from baseline measurements and
were also compared with age- and
sex-matched healthy controls
Total lymphocyte counts,
lymphocyte sub-populations,
PHA-induced proliferation of
PMC did not differ between
patients and controls at baseline
or during 12 week study period
PMC synthesis of IL-2 increased
five-fold after 4 weeks morphine
treatment (Po0.05)
IgM production from PMW cells
no longer possible after 4 weeks
morphine treatment
Impairment of spontaneous and
PWM-stimulated IgG production
No difference in IgG or IgM
between patients and controls at
baseline or during treatment
No clinical end points
Abbreviations: Ig¼ immunoglobulin; IL¼ interleukin; i.t.¼ intrathecal; i.v.¼ intravenous; LAK¼ lymphokine-activated killer; M3G¼morphine-3-glucuronide; M6G¼morphine-6-glucuronide;
MIP-1a¼macrophage inflammatory protein 1a; NK¼natural killer (cells); PHA¼phytohaemagglutin; p.o.¼oral; PMC¼peripheral mononuclear cell; PS¼performance status;
PMW¼pokeweed mitogen.
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tolerance make clinicians commonly reluctant to prescribe opioids,
even for patients with significant cancer-related pain (Pergolizzi
et al, 2008; Breuer et al, 2011). This is leading to the greater use of
non-pharmacologic methods of pain control such as the delivery of
opioids intrathecally, rather than in the form of long-term systemic
treatment. Radiation therapy and adjunctive treatments including
bisphosphonates and RANK ligand antibodies can also reduce bone
cancer pain, and vertebroplasty or balloon kyphoplasty offers good
pain relief from vertebral metastases (Terpos et al, 2014). The
possibility that morphine can directly influence proliferation,
apoptosis and metastatic potential of cancer cells and increase
tumour growth in animal models raises additional concerns that
opioids might promote disease progression (Gaspani et al, 2002;
Shavit et al, 2004; Afsharimani et al, 2011; Gach et al, 2011). Despite
these alternatives and their potential benefits, opioids continue to be
essential for the management of cancer pain. Indeed, it is possible
that the immunosuppressive effects of pain can be reversed by
certain opioids, as tramadol (but not morphine) can overcome the
capacity of surgical stress to decrease NK cell activity and enhance
tumour metastasis in preclinical models (Gaspani et al, 2002).
Immune cells express ORL1 when resting and the mu opioid
receptor, which is considered to be critical for immune cells to respond
directly to most commonly prescribed opioids, following activation
(Williams et al, 2007; Borner et al, 2008). Opioid receptor activation
triggers multiple downstream signalling events, which include decreas-
ing cyclic adenosine monophosphate (cAMP), increasing nitric oxide
and cyclic guanosine monophosphate levels, and the stimulation of
phospholipase C, mitogen-activated protein kinase (MAPK) and
protein kinase C (Kelly et al, 2008; Stefano et al, 2008). All of these
interactions ultimately interfere with immune cell activation pathways,
which involve cAMP and MAPK (Borner et al, 2008, 2009). Activated
immune cells can produce several opioid peptides (such as b-
endorphin) in addition to endogenous morphine that can bind to
opioid receptors present on peripheral nerves to induce analgesia (Stein
and Lang, 2009; Glattard et al, 2010). The presence of opioid receptors
on activated lymphoid cells suggests that endogenous opioids released
by such cells could also contribute to an inhibitory feedback loop
(Borner et al, 2008). These potential effects are summarised in Figure 2.
The immunoregulatory effects of morphine and some other
opioids can also be elicited by direct effects on immune cells
expressing non-opioid receptors such as Toll-like receptor 4
(TLR4) (Wang et al, 2002; Borner et al, 2008, 2009; Keiser et al,
2009; Hutchinson et al, 2010; Franchi et al, 2012). Opioids can also
have indirect effects that manifest via centrally produced mediators
such as immunosuppressive glucocorticoids that are released as a
consequence of hypothalamic pituitary adrenal axis activation, and
via effects on the sympathetic nervous system, which innervates
lymphoid organs (Figure 3; Wang et al, 2002).
Studies in rats have reported that oral morphine can suppress
T- and B-cell proliferation and NK cell activity (Van Der Laan
et al, 1996; West et al, 1997). Conversely, rodent models have
shown that tramadol, but not morphine, dose-dependently
increases NK cell cytotoxicity. Furthermore, tramadol, but not
morphine, reduces lung metastasis following the injection of
MADB106 mammary tumour cells into rats (Gaspani et al, 2002).
The capacity of tramadol to enhance immunity might be because
of its coexisting intrinsic serotonergic effect (Sacerdote et al, 2000;
Gaspani et al, 2002). In mice, a single subcutaneous dose of
fentanyl, but not buprenorphine, decreases lymphoproliferation in
response to the mitogen concanavalin A, but has no effect on NK
cell cytotoxicity (Martucci et al, 2004). A continuous infusion of
fentanyl has been shown to decrease lymphoproliferation and NK
cell cytotoxicity at 24 h, with NK cell cytotoxicity normalising by
day 3. However, tolerance to the effects on lymphoproliferation did
not develop until day 7 in these studies (Martucci et al, 2004).
Buprenorphine had no such effects. In a rodent surgical model, a
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Figure 2. Quadrangulation of the effects of opioids on pain, immunity
and cancer. Under normal circumstances opioids inhibit pain, which is
itself immunosuppressive (Page et al, 2001; Page, 2003). Some opioids
also have specific effects on immune function, either suppressive or
stimulatory, and the balance of these opioid-mediated effects
influences the progression of cancer (in animal models) (Gaspani et al,
2002). The immune system, via microglia and cytokines, influences the
pain state (Hutchinson et al, 2008). Activated immune cells can also
produce endogenous opioids, as well as morphine (Stein and Lang,
2009; Glattard et al, 2010). Cancer can also cause pain, by nociceptive,
neuropathic and inflammatory mechanisms. There is a dynamic
interaction of the immune system and cancer with immunoediting and
immunosculpting (Reiman et al, 2007). Furthermore, there are non-
immune effects of opioids on cancer cells (Gach et al, 2011). All of
these factors combine to create the net balance of cancer cell growth
or destruction (Page, 2005). The white arrows indicate a beneficial
effect on pain, immunity and cancer, and the solid arrows indicate a
detrimental effect on immunity and cancer.
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Figure 3. Peripheral and central mechanisms of opioid-induced
immune suppression. Different opioids can have direct effects on
immune cells, which express appropriate receptors such as mu-opioid
receptors (MORs) and TLR4. They can also have immunosuppressive
effects on specific immune cells via central mechanisms. Acute opioid
administration enhances activity in the periaqueductal gray (PAG)
matter, which activates the sympathetic nervous system (SNS). The SNS
innervates lymphoid organs, such as the spleen, and this activation
induces the release of biologic amines, which suppress splenic
lymphocyte proliferation and natural killer (NK) cell cytotoxicity
(Irwin et al, 1988; Fecho et al, 1996). Second, prolonged use of opioids
increases hypothalamic pituitary adrenal (HPA) axis activity and
glucocorticoid production, which decrease NK cell cytotoxicity
(Fecho et al, 1996; Mellon and Bayer, 1998). Morphine can also act via
D1 dopamine receptors in the nucleus accumbens shell, increasing the
release of neuropeptide Y (NPY) and reducing splenic NK cell
cytotoxicity in rodent models (Saurer et al, 2006).
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single dose of fentanyl increased suppression of NK cell activity
and resulted in more lung metastasis following the injection of
MADB106 tumour cells (Forget et al, 2010). Although NK cell
cytotoxicity in healthy volunteers is suppressed by morphine
(Yeager et al, 1995), fentanyl has been shown to increase the
number of circulating NK cells and NK cell cytotoxicity (Jacobs
et al, 1999; Yeager et al, 2002).
Although clinically relevant concentrations of morphine and
methadone have been shown to inhibit cytotoxicity of NK cells
from rats, monkeys and pigs (Molitor et al, 1992; Condevaux et al,
2001), such effects have not been seen in healthy volunteers, with
in vitro studies indicating that clinically relevant concentrations of
morphine, methadone, fentanyl and diamorphine do not influence
NK or T cells (Yeager et al, 1992; House et al, 1995, Thomas et al,
1995; Jacobs et al, 1999; Boland et al, 2013).
The preclinical data indicate that tramadol might be potentially
stimulating of the immune response (Gaspani et al, 2002) and
buprenorphine to be immune neutral (Martucci et al, 2004),
however until there are comparative studies with clinical end
points, no one opioid can be strongly recommended over another
in terms of their immune effects. Furthermore, cancers will have
differential effects on the immune status and immune regulatory
profiles and responses in one patient might not be broadly
applicable to all.
CONCLUSIONS
All studies discussed in this systematic review were prospective and
observational. They all used morphine and no study reported the
effects on clinical end points. Although the studies included in this
review add to the current body of knowledge of opioid effects on
the immune system, these findings cannot currently be extra-
polated to cancer patients on chronic opioids for pain owing to
differences in immune cell activation and opioid receptor
expression (Borner et al, 2008). As a consequence, there is
currently insufficient evidence on which to base a more rational
choice of opioids for optimising pain control without negatively
impacting on the patient’s essential protective immune function. It
is therefore hoped that clinically derived data will provide better
evidence in the future. In the meantime, judicious doses of opioids
should continue to be used as part of a multimodal approach for
the management of patients with cancer pain.
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